FOLD Earnings & Forecasts

FOLD (FOLD) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

Quarterly Earnings Surprise Amount

Fiscal Quarter	Date Reported	Actual EPS	Estimated EPS	Surprise %
Q4	Feb 20, 2026	$0.10	$0.14	-28.6 %
Q3	Nov 4, 2025	$0.17	$0.09	88.9 %
Q2	Jul 31, 2025	$0.01	$-0.01	200.0 %
Q1	May 1, 2025	$0.03	$0.08	-62.5 %

Quarterly Revenue (Billions)

Quarterly Revenue Surprise Amount

Fiscal Quarter	Date Reported	Actual Revenue	Estimated Revenue	Surprise %
Q4	Feb 20, 2026	$185.21M	$182.96M	1.23 %
Q3	Nov 4, 2025	$169.06M	$165.33M	2.26 %
Q2	Jul 31, 2025	$154.69M	$147.01M	5.22 %
Q1	May 1, 2025	$125.20M	$136.35M	-8.18 %

FOLD Guidance

FOLD (FOLD) last issued guidance on January 26, 2026 for fiscal year 2025. The company guided revenue in the range of $634M - $634M for the period.

Compared to prior guidance, FOLD raised its revenue forecast from a prior range of $607.54M - $644.52M.

FOLD has issued 12 guidance updates between January 9, 2023 and January 26, 2026. During this period, the company raised its outlook 6 times and lowered it 2 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Earnings Per Share (Non-GAAP)
Estimate	$0.14	$0.09	$-0.01	$0.08
Actual	$0.10	$0.17	$0.01	$0.03
Surprise	-28.6%	+88.9%	+200.0%	-62.5%
Revenue
Estimate	$183.0M	$165.3M	$147.0M	$136.3M
Actual	$185.2M	$169.1M	$154.7M	$125.2M
Surprise	+1.23%	+2.26%	+5.22%	-8.18%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E
Earnings Per Share (Non-GAAP)
Consensus	$0.13	$0.15
Revenue
Consensus	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

PRO
Amicus Therapeutics Q4 Adj. EPS $0.10 Beats $0.08 Estimate, Sales $185.213M Beat $179.764M Estimate

Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.08 by 19.05 percent. This is a 11.11 percent increase over earnings of $0.09 per share from

Benzinga Newsdesk

Nasdaq Surges Over 1%; Lamb Weston Shares Decline Following Q2 Results

Avi Kapoor

PRO
Amicus 2025 Outlook Reiterates Financial Guidance With Revenue Growth Target Of 15% To 22% Reflecting Continued Business Expansion

2025 Financial GuidanceAmicus reiterates its financial guidance for 2025, as follows:Total Revenue Growth115% to 22%Galafold Revenue Growth110% to 15%Pombiliti + Opfolda Revenue Growth150% to 65%Gross MarginMid

Benzinga Newsdesk

PRO
Amicus Therapeutics Q3 Adj. EPS $0.17 Beats $0.04 Estimate, Sales $169.061M Beat $165.706M Estimate

Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.04 by 335.9 percent. This is a 70 percent increase over earnings of $0.10 per share from

Benzinga Newsdesk

Earnings Scheduled For November 4, 2025

Benzinga Insights

PRO
Amicus Therapeutics Affirms FY2025 Sales Guidance of $607.539M-$644.520M vs $620.675M Est

2025 Financial GuidanceAmicus reiterates its financial guidance for 2025, as follows:Total Revenue Growth115% to 22% Galafold Revenue Growth110% to 15% Pombiliti + Opfolda Revenue Growth150% to 65% Gross

Benzinga Newsdesk

FOLD